8-K: NEXGEL Announces Record Preliminary Q3 2024 Revenue, Surpassing Expectations

NEXGEL reports preliminary record revenue of $2.85 million for Q3 2024, a 133% increase year-over-year and 98% sequentially, exceeding previous guidance.

Summary

• NEXGEL has announced preliminary, unaudited revenue of approximately $2.85 million for the third quarter of 2024.
• This represents a 133% increase in revenue compared to the same quarter last year.
• The revenue also shows a 98% increase compared to the previous quarter.
• The preliminary revenue figure is 30% higher than the company's previously issued guidance of $2.20 million for the third quarter.
• The company attributes the growth to strong performance in both branded consumer products and contract manufacturing.
• NEXGEL expects continued positive momentum into the fourth quarter, including the delivery of their first SilverSeal order to Cintas.
• The company will release its full financial results for Q3 2024 on or before November 14, 2024.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to the record revenue, significant growth rates, and exceeding of previous guidance. The company's expansion and future outlook also contribute to the high sentiment score.

Positives

• The company achieved record revenue in Q3 2024, reaching approximately $2.85 million.
• NEXGEL experienced substantial year-over-year revenue growth of 133%.
• The company also saw a significant sequential revenue increase of 98% compared to the previous quarter.
• The preliminary revenue exceeded the company's previous guidance by 30%.
• Both branded consumer products and contract manufacturing segments contributed to the strong revenue performance.
• The company's expansion initiatives, including doubling square footage and installing automated machinery, have positively impacted contract manufacturing revenue.
• NEXGEL expects continued positive momentum into the fourth quarter.

Negatives

• The reported results are preliminary and unaudited, subject to change upon completion of quarter-end adjustments.
• The actual results may differ materially from the current expectations expressed in the release.

Risks

• The preliminary financial results are subject to change as they are based on estimates and assumptions.
• Final adjustments and other developments may require material adjustments to the preliminary financial information.
• The company's actual results may differ materially from the current expectations expressed in the release.
• The company's forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.

Future Outlook

NEXGEL anticipates continued positive momentum into the fourth quarter of 2024, including the delivery of their first SilverSeal order to Cintas.

Management Comments

• Adam Levy, NEXGEL's CEO, stated that the company is pleased to announce another record revenue quarter, surpassing internal forecasts in both branded consumer products and contract manufacturing.
• He also noted that branded consumer product sales have seen significant growth year-over-year and quarter-over-quarter in all three brands, led by Silly George.
• Additionally, he mentioned that the contract manufacturing segment has returned to more normalized revenue levels following recent expansion initiatives.

Industry Context

This announcement indicates strong growth for NEXGEL in the medical and over-the-counter product market, particularly in hydrogels. The company's expansion and focus on both branded products and contract manufacturing appear to be paying off. The growth in the beauty brand Silly George is also notable.

Comparison to Industry Standards

• While specific competitor data isn't provided in this document, a 133% year-over-year revenue increase and 98% sequential increase are exceptionally high growth rates, suggesting NEXGEL is outperforming many of its peers in the medical and OTC product space.
• Companies like 3M, Johnson & Johnson, and Medline are major players in the broader healthcare and medical supply industry, but they typically don't experience such rapid growth rates due to their size and maturity.
• NEXGEL's focus on hydrogels and its dual approach of branded products and contract manufacturing may be giving it a competitive edge in a niche market.
• The company's expansion initiatives, including doubling its square footage and installing automated machinery, are likely contributing to its ability to scale and meet increasing demand, which is a key factor in outperforming industry standards.

Stakeholder Impact

• Shareholders are likely to react positively to the strong revenue growth and exceeding of guidance.
• Employees may be motivated by the company's success and expansion.
• Customers may benefit from the company's increased production capacity and product offerings.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower risk due to its improved financial performance.

Next Steps

• NEXGEL will finalize its financial results for the third quarter ended September 30, 2024.
• The company will report its full financial results on or before November 14, 2024.
• NEXGEL will host a conference call on the same day as the full financial results release.
• The company anticipates continued positive momentum into the fourth quarter, including the delivery of their first SilverSeal order to Cintas.

Key Dates

Keywords

revenue, NEXGEL, hydrogels, contract manufacturing, consumer products, financial results, preliminary results, Q3 2024, growth, SilverSeal